At the news
? BEARISHIMPACT 4/10 COURT-RULING filed Aug 6, 2026 at 20:00 ET
The Third Circuit reversed the District Court's dismissal of a TCPA class action against J&J subsidiaries, ruling that a two-page fax promoting Xarelto affordability via the Janssen CarePath program plausibly constitutes an unsolicited advertisement. The case now returns to the District Court for further proceedings, reviving litigation exposure for J&J on a claim that could involve statutory damages of $500 to $1,500 per unsolicited fax, potentially multiplied across a class. For a $624.7B market cap company, this is a low-probability, low-magnitude event, the ruling is a procedural reversal, not a damages award, and the underlying exposure is trivial relative to J&J's size.
- Third Circuit reversed District Court's dismissal of TCPA class action against J&J subsidiaries (Janssen Pharmaceuticals, J&J Health Care Systems).
- Court held that a two-page fax promoting Xarelto affordability via Janssen CarePath plausibly qualifies as an unsolicited advertisement under the TCPA.
- Case returns to District Court for further proceedings; no damages awarded, no injunction issued.
- Statutory damages under TCPA are $500 per violation, trebled to $1,500 for willful violations; potential class action exposure but no class certified yet.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access